# Jupiter Life Line Hospitals share price today (Jupiter Life Line Hospitals Ltd, NSE: JLHL)

> Jupiter Life Line Hospitals share price today: ₹279.55 at the NSE close on 4 November 2026, down 9.9% in a year. Jupiter Life Line Hospitals (NSE: JLHL) is worth ₹9,170 crore, trades at a P/E of 48.3 and has closed between ₹242.34 and ₹331.50 over the past 52 weeks. > Jupiter Life Line Hospitals Ltd's earnings have grown faster than its share price. Earnings per share grew +0.5% in a year while the price moved −9.9%. JLHL · Hospitals · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹279.55 (−9.9% in a year)
- P/E: 48.3× (lower than 68% of the last 3.1 years)
- Revenue (Sep 2026): ₹456 Cr (+15.7% on a year ago)
- Profit (Sep 2026): ₹56.0 Cr (−1.8% on a year ago)
- Operating margin: 23.0% (flat on a year ago)
- ROCE: 15%, FY26
- ROIC: 11.2%, against a 12.0% cost of capital: −0.8 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Jupiter Life Line Hospitals share price today? Jupiter Life Line Hospitals Ltd's share price was ₹279.55 at the close on 4 November 2026. It has been falling for 2 weeks. That is 1.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. In the last 52 weeks it traded between ₹242 and ₹332, and at that close it sat 42% of the way up from that low. Over the last 3.1 years the share price moved +31% while the NIFTY 500 moved +26%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Jupiter Life Line Hospitals this quarter? Two changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) and highest quarterly revenue in 16 quarters. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹456 crore, +15.7% on a year earlier. 2. Highest quarterly revenue in 16 quarters Revenue of ₹456 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are Jupiter Life Line Hospitals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Jupiter Life Line Hospitals reported revenue of ₹456 crore, up 15.7% from ₹394 crore a year earlier, and a profit of ₹56.0 crore, down 1.8% from ₹57.0 crore. ### Jupiter Life Line Hospitals results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹456 crore | ₹394 crore | +15.7% |
| Profit | ₹56.0 crore | ₹57.0 crore | −1.8% |
| Earnings per share | ₹1.71 | ₹1.75 | −2.3% |
| Operating margin | 23.0% | 23.0% | 0.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 18 May 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Jupiter Life Line Hospitals share price history? Jupiter Life Line Hospitals closed at ₹279.55 on 4 November 2026, down 9.9% from ₹310.38 a year earlier (7 November 2025) and up 37.3% over three years. Its highest weekly close since September 2023 was ₹331.50 on 31 July 2026. ### Jupiter Life Line Hospitals share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹257.15 | +8.7% |
| 1 month ago · 1 Oct 2026 | ₹259.85 | +7.6% |
| 6 months ago · 8 May 2026 | ₹249.84 | +11.9% |
| 1 year ago · 7 Nov 2025 | ₹310.38 | −9.9% |
| 3 years ago · 3 Nov 2023 | ₹203.62 | +37.3% |
| Earliest weekly close in our records · 22 Sep 2023 | ₹212.76 | +31.4% |
| Highest weekly close since September 2023, also the 52-week high · 31 Jul 2026 | ₹331.50 | −15.7% |
| Lowest weekly close since September 2023 · 17 Nov 2023 | ₹199.88 | +39.9% |
| 52-week low (weekly close) · 20 Feb 2026 | ₹242.34 | +15.4% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (169 weekly closes from 22 September 2023 to 4 November 2026.)

## What is the latest news on Jupiter Life Line Hospitals? 4 Nov 2026: Jupiter Life Line Hospitals closed at ₹279.55, up 8.7% on the week and up 7.6% on the month. Results for July to September 2026: Revenue up 15.7% and profit down 1.8% on a year earlier. ### Earlier

- 24 Jul 2026: Share split: face value cut from ₹10 to ₹2 a share (ex-date). - 22 May 2026: ex-date for an interim dividend of ₹1 a share. - 18 May 2026: Jupiter Life Line Hospitals held its results call for January to March 2026. Management guided: Dombivli operating profit burn ₹2-3 crore per month average, operating profit breakeven end two years of operations (CY28 end, January to March 2028)

## What dividend does Jupiter Life Line Hospitals pay? Jupiter Life Line Hospitals paid ₹0.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.07% at the ₹279.55 close on 4 November 2026. The last was an interim dividend of ₹1 a share, ex-date 22 May 2026. ### Jupiter Life Line Hospitals dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 22 May 2026 | ₹1 | Interim |
| 4 Jul 2025 | ₹1 | Dividend |
| 2 Aug 2024 | ₹1 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 1 of the last 12 months' payments came before a split or bonus; the 12-month total above is on today’s share count. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Jupiter Life Line Hospitals Ltd paid out 3% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Jupiter Life Line Hospitals management say on the latest results call? On the call for January to March 2026, held on 18 May 2026, Jupiter Life Line Hospitals' management guided: Dombivli operating profit burn ₹2-3 crore per month average, operating profit breakeven end two years of operations (CY28 end, January to March 2028)

> “With BKC in the pipeline, we are looking at approximately 1,700 new beds in this expansion cycle, taking our long-term capacity to nearly 3,000 beds - that is a network we believe will be genuinely differentiated and will cement our position as the leading hospital group in Western India”
> Dr. Ankit Thakker, on the call for January to March 2026

### What management guided

- Pune South opening CY28; Mira Road excavation begin end CY26 on completion of regulatory clearances. - Thane hospital expansion final regulatory approvals expected sometime in FY27; exact scope to be determined post clearance. - Indore next phase 111 beds contingent on occupancy crossing 60.0% threshold. - Base business growth: Thane inflation-linked only (at capacity); Pune inflation plus occupancy gains; Indore case mix plus occupancy plus inflation. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/55918/Conference Call/CC-May26.pdf). (From the call for January to March 2026, 18 May 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Jupiter Life Line Hospitals' next results? When Jupiter Life Line Hospitals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Dombivli July to September 2026 occupancy ramp rate and insurance empanelment progress - two months operations insufficient for meaningful trajectory per management; Q2 data expected to provide >100 bed occupancy confirmation and insurance timeline clarity. - What to check (from the call)
- Dombivli July to September 2026 occupancy ramp rate and insurance empanelment progress - two months operations insufficient for meaningful trajectory per management; Q2 data expected to provide >100 bed occupancy confirmation and insurance timeline clarity. - Thane hospital additional floors regulatory approval finalization and scope confirmation - interim approvals in hand; final approval stage expected in FY27 with capital spending and bed addition details. - Indore occupancy crossing 60.0% threshold to trigger 111-bed next phase - currently 45.0%-50.0%; trajectory will signal case mix and utilization improvement pace and indicate phase timing. - ARPOB realization across hospitals and insurance renewal cycle impact sustainability - monitor whether biennial insurance renewals continue delivering price increases and Indore case mix maturation maintains growth momentum. ## Which stock lists is Jupiter Life Line Hospitals on? Jupiter Life Line Hospitals is not on any of our India lists this week. ## Is Jupiter Life Line Hospitals profitable? Jupiter Life Line Hospitals Ltd earned ₹56.0 Cr of net profit in the Sep 2026 quarter, −1.8% on the same quarter a year earlier. Full-year FY26 profit was ₹194 Cr. Over 6 years profit has grown 36.5% a year on average. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹57.0 Cr. For the full year, FY26 profit was ₹194 Cr (+0.0% on the year before). Why profit moved: revenue changed +15.7% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −5.9% and revenue +14.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Jupiter Life Line Hospitals make, and is it growing? Jupiter Life Line Hospitals Ltd reported ₹456 Cr of revenue in the Sep 2026 quarter, +15.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 6 years it has grown 21.6% a year on average. The last full year, FY26, came in at ₹1,500 Cr. The last four reported quarters add to ₹1,620 Cr. FY26 revenue was ₹1,500 Cr, +15.2% on the year before. Recent pace: the last four quarters grew +14.2% on average, against 21.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.3%, against +16.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −6.1%, against +0.0% a year (rolling over). ## How much of every ₹100 of sales does Jupiter Life Line Hospitals keep? Jupiter Life Line Hospitals Ltd's operating margin was 23.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 14.0% and 23.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Jupiter Life Line Hospitals' profit turning into cash? Over the last 3 years, 115% of Jupiter Life Line Hospitals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹268 Cr of operating cash against ₹194 Cr of profit. After ₹438 Cr of spending on assets, free cash was −₹170 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 115% of profit came in as cash: the cash cycle got 98 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building. ## Where does Jupiter Life Line Hospitals' cash go? Jupiter Life Line Hospitals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −54 days in FY26, up from −152 days in FY21. It spent ₹951 Cr on assets over the last 3 years. Customers take 18 days to pay, and stock sits for 49 days on average. At FY26 sales of ₹1,500 Cr, each day of that cycle ties up about ₹4.1 Cr, so roughly −₹222 Cr is tied up in the business at any time. FY26: customers took 18 days to pay and stock sat for 49 days, about 1.6 months of sales sitting as stock, for a full cycle of −54 days, longer than FY21's −152. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 49 days. Customers pay about 18 days after that. Suppliers are paid at 121 days. Together that makes the −54-day cycle. Spending on assets: ₹951 Cr over the last 3 years, against ₹187 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹129 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Jupiter Life Line Hospitals' P/E ratio, and how does it compare with its own history? Jupiter Life Line Hospitals Ltd's P/E is 48.3×, near the low end of its own history: it has been lower only 32% of the time. Its usual P/E (the middle reading) is 50.5×, over 3.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹5.68. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +0.5% while the price moved −9.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +11.1% a year; about +36.8% a year came from earnings growth and about −25.7 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Jupiter Life Line Hospitals business getting better or worse? Jupiter Life Line Hospitals Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −6.1% in the latest quarter, against +142.5% at its best in 12 quarters, with ROCE falling at 14.2%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Jupiter Life Line Hospitals earn on its capital? Jupiter Life Line Hospitals Ltd earned a ROCE of 15% in FY26. That is up from a low of 7% in FY21. Its return on capital used (ROIC) is 0.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 12.9% net margin and 0.63× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.9% net margin × 0.63× asset turnover × 1.53× leverage (assets divided by equity) ≈ 12.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 11.2% − 12.0% = −0.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 11.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 14.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Jupiter Life Line Hospitals have too much debt? Jupiter Life Line Hospitals Ltd has total debt of ₹669 Cr against shareholder equity of ₹1,631 Cr as of Sep 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 1.29 in FY23 to 0.38 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Jupiter Life Line Hospitals shareholding pattern? Domestic institutions raised their stake in Jupiter Life Line Hospitals Ltd by 5.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 19.1% of the company. Foreign institutions moved +0.3 points over the same period, to 9.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +5.7 points over 8 quarters, to 19.1%; Foreign institutions: +0.3 points over 8 quarters, to 9.1%; Promoters: +0.0 points over 8 quarters, to 40.9%. Why the owners changed: domestic institutions drove it (+5.7 points). They raised their stake step by step. ## How far is Jupiter Life Line Hospitals from balance-sheet trouble? For Jupiter Life Line Hospitals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Jupiter Life Line Hospitals rank in its industry? 33.0 out of 100, rank 18 of 20 in Hospitals, with 100% of the evidence available. Jupiter Life Line Hospitals Ltd scores 33.0 out of 100 against the 20 companies it is compared with in Hospitals, ranking 18. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 9.2 + 11.3 + 8.4 + 4.1 = 33. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Jupiter Life Line Hospitals compared with? Jupiter Life Line Hospitals ranks 18 of 20 Hospitals companies on the 4-Factor Sector Score, with 33.0 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.0/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23 + 14.1 + 12.5 = 80.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.4/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.4 + 11.1 + 13.8 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.3 + 12.5 + 11.6 = 62.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.1/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.1 + 18.5 + 9.1 = 61.1 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.7/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.7 + 8 + 16.7 = 56.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 18.8/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 18.8 + 5.5 + 14.2 = 52 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 10. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.5 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.7 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.0 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. Jupiter Life Line Hospitals Ltd this page JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.2/35 · Revenue 14.3% · Profit -6.1% · Operating margin change 0 points · 100% evidence Capital efficiency 11.3/25 · ROCE 14.8% · Operating margin 23% · 100% evidence Valuation 8.4/20 · P/E 44.4× · PEG 3.71 · 100% evidence Relative strength 4.1/20 · Lead over its industry -5.5% · Lead over NIFTY 500 -1.2% · 1 year -19% · 100% evidence · 6 of 12 weeks ahead Exact sum: 9.2 + 11.3 + 8.4 + 4.1 = 33 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Jupiter Life Line Hospitals in size? Jupiter Life Line Hospitals is the 12th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Rainbow Childrens Medicare, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises. Just below it: Kovai Medical Center & Hospital, Artemis Medicare Services and Indraprastha Medical Corporation. ### Hospitals companies close in size

1. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) ₹12,378 crore
2. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) ₹8,931 crore
3. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) ₹8,742 crore
4. Jupiter Life Line Hospitals Ltd ₹8,430 crore
5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹6,363 crore
6. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹4,642 crore
7. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) ₹2,802 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Finolex Industries Ltd](https://www.sectoralpha.in/stocks/finolex-industries-ltd) ₹8,510 crore · Building Materials - Plastic Pipes
2. [Jayaswal Neco Industries Ltd](https://www.sectoralpha.in/stocks/jayaswal-neco-industries-ltd) ₹8,454 crore · Mining/Minerals - Iron Ore
3. Jupiter Life Line Hospitals Ltd ₹8,430 crore
4. [AAVAS Financiers Ltd](https://www.sectoralpha.in/stocks/aavas-financiers-ltd) ₹8,428 crore · Finance - Housing
5. [Genus Power Infrastructures Ltd](https://www.sectoralpha.in/stocks/genus-power-infrastructures-ltd) ₹8,321 crore · Electronics - Equipment/Components

## What else do people ask about Jupiter Life Line Hospitals? ### What is Jupiter Life Line Hospitals's share price today? Jupiter Life Line Hospitals Ltd's share price is ₹279.55, −9.9% over the past year. The whole company is worth ₹9,170 Cr on the market. In the last 52 weeks it traded between ₹242 to ₹332; today it is 42% of the way up from the low, 1.1% above its 200-day average (as of 4 November 2026). ### What were Jupiter Life Line Hospitals's latest quarterly results? Jupiter Life Line Hospitals Ltd reported revenue of ₹456 Cr and net profit of ₹56.0 Cr for the Sep 2026 quarter. Revenue rose 15.7% and profit fell 1.8% compared with a year earlier. Earnings per share were ₹1.71 (as of 4 November 2026). ### What is Jupiter Life Line Hospitals's market cap? Jupiter Life Line Hospitals Ltd's market capitalisation is ₹9,170 Cr at a share price of ₹279.55. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Jupiter Life Line Hospitals performing? Jupiter Life Line Hospitals Ltd's share price has been falling for 2 weeks. In its latest quarter, revenue rose 15.7% and profit fell 1.8% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 7 weeks running (as of 4 November 2026). ### Will Jupiter Life Line Hospitals's share price go up? This page does not forecast Jupiter Life Line Hospitals Ltd's share price. What it shows instead: the share price is ₹279.55, and it has been falling for 2 weeks. Its P/E of 48.3× is higher than 32% of its own last 3 years (as of 4 November 2026). ### Who owns Jupiter Life Line Hospitals? Promoters own 40.9% of Jupiter Life Line Hospitals Ltd, foreign institutions 9.1%, domestic institutions 19.1% and the public 30.9% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 5.7 percentage points over 8 quarters (as of 4 November 2026). ### Does Jupiter Life Line Hospitals have too much debt? Jupiter Life Line Hospitals Ltd has a moderate amount of debt: its debt is 0.38× its equity, and its operating profit is 10 times its interest bill. FY26 borrowings were ₹584 Cr against equity of ₹1,545 Cr. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Jupiter Life Line Hospitals in its business cycle? Jupiter Life Line Hospitals Ltd's FY26 operating margin was 23.0%, against a 7-year range of 14.0% to 23.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 23.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Jupiter Life Line Hospitals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Jupiter Life Line Hospitals a stock worth studying right now? What the numbers show: Jupiter Life Line Hospitals Ltd's earnings have grown faster than its share price. Earnings per share grew +0.5% in a year while the price moved −9.9%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Jupiter Life Line Hospitals share price forecast for 2026? What management itself guided: Dombivli operating profit burn ₹2-3 crore per month average, operating profit breakeven end two years of operations (CY28 end, January to March 2028)

This is research, not advice. We’re not SEBI-registered.